In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Impax acquires generic drug portfolio from Teva; Teva returns rights to ANDA for generic Concerta

Executive Summary

Impax Laboratories Inc. acquired a portfolio of 18 marketed, approved and pipeline generics from Teva Pharmaceutical Industries Ltd. and Allergan affiliates for $586mm (funded from $400mm in new term loans with the balance from cash on hand). The product divestitures were mandated by the FTC as a condition of Teva's pending acquisition of Allergan's global generics business (just last week Teva sold off the rights to eight ANDAs to Dr. Reddy's.)

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Product Purchase

Related Companies